Genome Editing Market

Genome Editing Market [Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-like Effector Nuclease (TALEN), Zinc Finger Nuclease (ZFN), and Other Technologies] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Genome Editing Market Outlook 2031

  • The global industry was valued at US$ 5.5 Bn in 2022
  • It is projected to advance at a CAGR of 13.9% from 2023 to 2031 and reach more than US$ 17.5 Bn by the end of 2031

Analysts’ Viewpoint

Increase in prevalence of genetic disorders, surge in demand for personalized medicine, and expanding applications of genome editing technologies in therapeutic areas are fueling the genome editing market size.

Furthermore, the emergence of CRISPR-Cas9 as a versatile and precise genome editing tool offers lucrative opportunities for market expansion, enabling researchers to edit genes with unprecedented accuracy.

The rise in demand for genome editing tools and services across research institutions, biopharmaceutical companies, and clinical settings is driving market progress. A notable trend is the growth in adoption of CRISPR technology for developing gene therapies and the utilization of genome editing in agriculture for crop improvement.

The genome editing market continues to evolve, indicating a promising future as it addresses critical healthcare needs and contributes to advancements in various scientific domains.

Market Introduction

Genome editing is a revolutionary technique that enables precise modification of an organism's DNA, allowing scientists to add, delete, or alter specific genetic elements. Its applications span a wide range of fields, including agriculture, medicine, and biotechnology.

In agriculture, genome editing can be used to create crops with improved traits such as resistance to pests and diseases, increased yield, and enhanced nutritional content.

In medicine, genome editing holds promise to treat genetic disorders by correcting or replacing faulty genes. The CRISPR-Cas9 system, a groundbreaking genome-editing tool, has significantly accelerated research in this area. The technique has undergone continuous refinement, leading to increased accuracy and reduced off-target effects.

Scientists are exploring new editing techniques, such as base editing and prime editing, which offer improved precision and reduced unintended alterations. Ethical considerations involve discussions about the responsible use of genome editing, particularly in the context of human germline editing.

Growth in Demand for Personalized Medicine Driving Genome Editing Market Growth

Personalized medicine, an approach that tailors medical treatment to individual characteristics, is gaining immense traction due to its potential to enhance therapeutic outcomes and minimize adverse effects.

As the understanding of the human genome advances, there is an increasing realization that generic treatments may not be optimal for every patient. The demand for personalized medicine arises from the need to address this individual variability in drug response and disease susceptibility.

In the realm of personalized medicine, genome editing holds the promise of developing targeted therapies that can be tailored to the genetic profile of each patient. This approach has the potential to revolutionize the treatment of various genetic disorders, cancers, and other diseases with a genetic component. The ability to edit genes at the molecular level enables the correction of genetic mutations, paving the way for more effective and safer treatment options.

Pharmaceutical companies, biotechnology firms, and research institutions are investing heavily in genome editing technologies to create a new generation of therapies that can be precisely calibrated to the genetic nuances of each patient.

The growth in demand for personalized medicine is a key factor propelling the genome editing market revenue, promising a future where medical treatments are increasingly tailored to the individual, ushering in a new era of precision medicine.

Surge in Incidence of Genetic Disorders Fueling Market Development

Genetic disorders, often rooted in the individual's DNA, present a significant and rising healthcare challenge globally. The surge in genetic disorders has triggered an unprecedented demand for advanced therapeutic interventions, fostering the genome editing market growth.

As genetic disorders manifest with distinct genetic variations in affected individuals, a one-size-fits-all approach to treatment proves insufficient. Precision allows for tailored therapeutic solutions, aligning with the principles of personalized medicine.

Genome editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, provide precise tools for manipulating the genetic code, allowing scientists and clinicians to modify or correct specific genes associated with diseases.

Additionally, the genome editing market is witnessing a surge in research & development activities aimed at addressing specific genetic anomalies associated with various disorders. The prospect of correcting faulty genes responsible for diseases holds immense promise in the quest for effective treatments and cures.

Consequently, pharmaceutical and biotechnology companies are investing heavily in genome editing technologies to meet the burgeoning demand for personalized therapeutic interventions.

CRISPR Gaining Traction

The genome editing market segmentation based on technology includes Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-like Effector Nuclease (TALEN), Zinc Finger Nuclease (ZFN), and other technologies.

Simplicity, versatility, and cost-effectiveness have enabled CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to emerge as the frontrunner in the genome editing market.

CRISPR offers a more user-friendly approach, enabling a broader scientific community to adopt and implement genome editing techniques. CRISPR allows researchers to quickly adapt and target different genes by simply redesigning the guide RNA. This adaptability accelerates the pace of research & development in various fields, from agriculture to medicine.

Genome Editing Market Concerns

Ethical concerns surrounding gene editing, the potential for off-target effects, and regulatory uncertainties are likely to restrain the market. Additionally, the high cost associated with genome editing technologies poses a barrier to widespread adoption. The COVID-19 pandemic further impacted the market, disrupting supply chains and diverting resources toward pandemic-related research.

The evolving landscape of genome editing promises transformative impacts on agriculture, medicine, and beyond, but careful consideration and responsible implementation are essential as the technology continues to advance.

Regional Outlook of Genome Editing Industry

As per the latest genome editing market forecast, North America currently holds a dominant position that reflects its advanced technological infrastructure, well-established healthcare system, and robust research & development activities.

A strong emphasis on biotechnological advancements, significant investments in genomic research, and a high prevalence of genetic disorders further drive market dynamics in the region. The presence of major market players, academic institutions, and biotech firms dedicated to genome editing technologies also propels North America's dominance.

Asia Pacific is an expanding market for genome editing technologies. Surge in awareness and adoption of personalized medicine in the region and a rising population and growth in focus on precision healthcare is leading to heightened demand for advanced genomic tools and therapies. A large pool of skilled researchers and scientists foster innovation and advancements in genome editing in the region.

Analysis of Key Players

The genome editing market report provides profiles of leading players. Merck KGaA, AstraZeneca, Takara Bio Inc., Cellectis SA, CRISPR Therapeutics., Cibus Inc., RECOMBINETICS, Sangamo Therapeutics, and Thermo Fisher Scientific, Inc. are the key entities operating in this market.

These players engage in mergers & acquisitions, strategic collaborations, and new product launches to expand their presence and gain substantial market share.

Key companies have been profiled in the report based on various factors including company overview, financial summary, strategies, product portfolio, segments, and recent advancements.

Key Developments

  • In February, 2022, Intellia Therapeutics, Inc., a clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, announced acquisition of Rewrite Therapeutics, Inc., a private biotechnology company focused on advancing novel DNA writing technologies. Rewrite’s technology will be delivered using Intellia’s lipid nanoparticle (LNP) technology and adeno-associated virus (AAV) vectors.
  • In November 2020, Eli Lilly and Company and Precision BioSciences, Inc. announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

Genome Editing Market Snapshot

Attribute Detail
Market Size in 2022 US$ 5.5 Bn
Market Forecast (Value) in 2031 More than US$ 17.5 Bn
Growth Rate (CAGR) 2023-2031 13.9%
Forecast Period 2023-2031
Historical Data Available for 2017-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional-level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation
  • Technology
    • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
    • Transcription Activator-like Effector Nuclease (TALEN)
    • Zinc Finger Nuclease (ZFN)
    • Other Technologies
  • Application
    • Cell Line Editing
    • Animal Genome Editing
    • Plant Genome Editing
    • Others
  • End-user
    • Pharmaceutical Companies and Biotechnology Companies
    • Academics and Government Research Institutes
    • Clinical Research Organizations
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Merck KGaA
  • AstraZeneca
  • Takara Bio Inc.
  • Cellectis SA
  • CRISPR Therapeutics.
  • Cibus Inc.
  • RECOMBINETICS
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global genome editing market in 2022?

It was valued at US$ 5.5 Bn in 2022

How big will the genome editing industry be in 2031?

It is projected to reach more than US$ 17.5 Bn by the end of 2031

What will be the CAGR of the genome editing business during the forecast period?

The CAGR is anticipated to be 13.9% from 2023 to 2031

What is the share of the leading segment in the genome editing sector?

Based on technology, the CRISPR segment accounted for largest share in 2022

Which region will account for a major share of the genome editing landscape during the forecast period?

North America is anticipated to account for leading share during the forecast period.

Who are the prominent genome editing players?

Merck KGaA, AstraZeneca, Takara Bio Inc., Cellectis SA, CRISPR Therapeutics., Cibus Inc., RECOMBINETICS, Sangamo Therapeutics, and Thermo Fisher Scientific, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Genome Editing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Genome Editing Market Analysis and Forecasts, 2017-2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Regulatory Scenario

        5.2. Technological Advancements

        5.3. Covid-19 Pandemic Impact on Industry

    6. Global Genome Editing Market Analysis and Forecasts, By Technology

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Technology, 2017-2031

            6.3.1. Clustered regularly interspaced short palindromic repeats (CRISPR)

            6.3.2. Transcription activator-like effector nuclease (TALEN)

            6.3.3. Zinc finger nuclease (ZFN)

            6.3.4. Other technologies

        6.4. Market Attractiveness By Technology

    7. Global Genome Editing Market Analysis and Forecasts, By Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Application, 2017-2031

            7.3.1. Cell Line Editing

            7.3.2. Animal Genome Editing

            7.3.3. Plant Genome Editing

            7.3.4. Others

        7.4. Market Attractiveness By Application

    8. Global Genome Editing Market Analysis and Forecasts, By End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By End-user, 2017-2031

            8.3.1. Pharmaceutical Companies and Biotechnology Companies

            8.3.2. Academics and Government Research Institutes

            8.3.3. Clinical Research Organizations

        8.4. Market Attractiveness By End-user

    9. Global Genome Editing Market Analysis and Forecasts, By Region

        9.1. Key Findings

        9.2. Market Value Forecast By Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness By Country/Region

    10. North America Genome Editing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast By Technology, 2017-2031

            10.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)

            10.2.2. Transcription activator-like effector nuclease (TALEN)

            10.2.3. Zinc finger nuclease (ZFN)

            10.2.4. Other technologies

        10.3. Market Value Forecast By Application, 2017-2031

            10.3.1. Cell Line Editing

            10.3.2. Animal Genome Editing

            10.3.3. Plant Genome Editing

            10.3.4. Others

        10.4. Market Value Forecast By End-user, 2017-2031

            10.4.1. Pharmaceutical Companies and Biotechnology Companies

            10.4.2. Academics and Government Research Institutes

            10.4.3. Clinical Research Organizations

        10.5. Market Value Forecast By Country, 2017-2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Technology

            10.6.2. By Application

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Genome Editing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Technology, 2017-2031

            11.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)

            11.2.2. Transcription activator-like effector nuclease (TALEN)

            11.2.3. Zinc finger nuclease (ZFN)

            11.2.4. Other technologies

        11.3. Market Value Forecast By Application, 2017-2031

            11.3.1. Cell Line Editing

            11.3.2. Animal Genome Editing

            11.3.3. Plant Genome Editing

            11.3.4. Others

        11.4. Market Value Forecast By End-user, 2017-2031

            11.4.1. Pharmaceutical Companies and Biotechnology Companies

            11.4.2. Academics and Government Research Institutes

            11.4.3. Clinical Research Organizations

        11.5. Market Value Forecast By Country, 2017-2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Technology

            11.6.2. By Application

            11.6.3. By End-user

            11.6.4. By Country

    12. Asia Pacific Genome Editing Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Technology, 2017-2031

            12.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)

            12.2.2. Transcription activator-like effector nuclease (TALEN)

            12.2.3. Zinc finger nuclease (ZFN)

            12.2.4. Other technologies

        12.3. Market Value Forecast By Application, 2017-2031

            12.3.1. Cell Line Editing

            12.3.2. Animal Genome Editing

            12.3.3. Plant Genome Editing

            12.3.4. Others

        12.4. Market Value Forecast By End-user, 2017-2031

            12.4.1. Pharmaceutical Companies and Biotechnology Companies

            12.4.2. Academics and Government Research Institutes

            12.4.3. Clinical Research Organizations

        12.5. Market Value Forecast By Country, 2017-2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Technology

            12.6.2. By Application

            12.6.3. By End-user

            12.6.4. By Country

    13. Latin America Genome Editing Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Technology, 2017-2031

            13.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)

            13.2.2. Transcription activator-like effector nuclease (TALEN)

            13.2.3. Zinc finger nuclease (ZFN)

            13.2.4. Other technologies

        13.3. Market Value Forecast By Application, 2017-2031

            13.3.1. Cell Line Editing

            13.3.2. Animal Genome Editing

            13.3.3. Plant Genome Editing

            13.3.4. Others

        13.4. Market Value Forecast By End-user, 2017-2031

            13.4.1. Pharmaceutical Companies and Biotechnology Companies

            13.4.2. Academics and Government Research Institutes

            13.4.3. Clinical Research Organizations

        13.5. Market Value Forecast By Country, 2017-2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Technology

            13.6.2. By Application

            13.6.3. By End-user

            13.6.4. By Country

    14. Middle East & Africa Genome Editing Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Technology, 2017-2031

            14.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)

            14.2.2. Transcription activator-like effector nuclease (TALEN)

            14.2.3. Zinc finger nuclease (ZFN)

            14.2.4. Other technologies

        14.3. Market Value Forecast By Application, 2017-2031

            14.3.1. Cell Line Editing

            14.3.2. Animal Genome Editing

            14.3.3. Plant Genome Editing

            14.3.4. Others

        14.4. Market Value Forecast By End-user, 2017-2031

            14.4.1. Pharmaceutical Companies and Biotechnology Companies

            14.4.2. Academics and Government Research Institutes

            14.4.3. Clinical Research Organizations

        14.5. Market Value Forecast By Country, 2017-2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Technology

            14.6.2. By Application

            14.6.3. By End-user

            14.6.4. By Country

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Share Analysis By Company (2022)

        15.3. Company Profiles

            15.3.1. Merck KGaA

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. AstraZeneca

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Takara Bio Inc.

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Cellectis SA

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. CRISPR Therapeutics

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Cibus Inc.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. RECOMBINETICS

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Sangamo Therapeutics

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Thermo Fisher Scientific, Inc.

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 02: Global Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 03: Global Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 04: Global Genome Editing Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 05: North America Genome Editing Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 06: North America Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 07: North America Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 08: North America Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 09: Europe Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 10: Europe Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 11: Europe Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 12: Europe Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 13: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 14: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 15: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 16: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 17: Latin America Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 19: Latin America Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 20: Latin America Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 21: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 23: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 24: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    List of Figures

    Figure 01: Global Genome Editing Market Size, by Technology, 2022

    Figure 02: Global Genome Editing Market Share (%), by Technology, 2022

    Figure 03: Global Genome Editing Market Size, by Application, 2022

    Figure 04: Global Genome Editing Market Share (%), by Application, 2022

    Figure 05: Global Genome Editing Market Size, by End-user, 2022

    Figure 06: Global Genome Editing Market Share (%), by End-user, 2022

    Figure 07: Global Genome Editing Market, by Region (2022-2031)

    Figure 08: Global Genome Editing Market Value (US$ Mn) Forecast, 2017-2031

    Figure 09: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031

    Figure 10: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022

    Figure 11: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2031

    Figure 12: Global Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 13: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031

    Figure 14: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022

    Figure 15: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2031

    Figure 16: Global Genome Editing Market Attractiveness Analysis, by Application, 2023-2031

    Figure 17: Global Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031

    Figure 18: Global Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022

    Figure 19: Global Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2031

    Figure 20: Global Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 21: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Region, 2022-2031

    Figure 22: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Region, 2022

    Figure 23: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Region, 2031

    Figure 24: Global Genome Editing Market Attractiveness Analysis, by Region, 2023-2031

    Figure 25: North America Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 26: North America Genome Editing Market Value Share Analysis, by Country, 2022-2031

    Figure 27: North America Genome Editing Market Attractiveness Analysis, by Country, 2023-2031

    Figure 28: North America Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031

    Figure 29: North America Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 30: North America Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031

    Figure 31: North America Genome Editing Market Attractiveness Analysis, by Application, 2023-31

    Figure 32: North America Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031

    Figure 33: North America Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 34: Europe Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 35: Europe Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 36: Europe Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 37: Europe Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031

    Figure 38: Europe Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 39: Europe Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031

    Figure 40: Europe Genome Editing Market Attractiveness Analysis, by Application, 2023-2031

    Figure 41: Europe Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031

    Figure 42: Europe Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 43: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 44: Asia Pacific Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 45: Asia Pacific Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 46: Asia Pacific Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031

    Figure 47: Asia Pacific Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 48: Asia Pacific Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031

    Figure 49: Asia Pacific Genome Editing Market Attractiveness Analysis, by Application, 2023-2031

    Figure 50: Asia Pacific Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031

    Figure 51: Asia Pacific Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 52: Latin America Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 53: Latin America Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 54: Latin America Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 55: Latin America Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031

    Figure 56: Latin America Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 57: Latin America Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031

    Figure 58: Latin America Genome Editing Market Attractiveness Analysis, by Application, 2023-2031

    Figure 59: Latin America Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031

    Figure 60: Latin America Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 61: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 62: Middle East & Africa Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 63: Middle East & Africa Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 64: Middle East & Africa Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031

    Figure 65: Middle East & Africa Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 66: Middle East & Africa Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031

    Figure 67: Middle East & Africa Genome Editing Market Attractiveness Analysis, by Application, 2023-2031

    Figure 68: Middle East & Africa Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031

    Figure 69: Middle East & Africa Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved